Background: β-blockers (BBs) are considered primary therapy in stable heart failure (HF) with reduced ejection fraction (HFrEF) without atrial fibrillation (AF); evidence-based benefits of BBs on outcome have been documented. However, BBs have not been shown to improve mortality or reduce hospital admissions in HF patients with AF. This study assessed the relationship between BBs at discharge and relevant clinical outcomes in acute heart failure (AHF) patients with AF.

Methods: From the Korean Acute Heart Failure Registry, 936 HFrEF and 639 HF patients with preserved ejection fraction (HFpEF) and AF were selected. Propensity score (PS) matching accounted for BB selection bias when assessing associations.

Results: BB-untreated patients in the overall cohort of HFrEF and HFpEF had greater deteriorated clinical and laboratory characteristics. In the 670 PS-matched cohort of HFrEF patients, incidences of all clinical events at 60 days and 1 year were not different according to use of BBs. In the 470 PS-matched cohort of HFpEF, rehospitalization and composite outcome at 6 months and 1 year more frequently occurred in non-users of BBs. After adjusting for covariates in the multivariable Cox model of matched cohorts, BB was not associated with clinical outcomes at 60 days and 1 year in HFrEF with AF patients. In HFpEF patients with AF, BB use was associated with reduced 6-month (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.20–0.74) and 1-year rehospitalization (HR, 0.53; 95% CI, 0.34–0.82).

Conclusion: In the HFrEF with AF PS-matched cohort, the use of BBs at discharge was not associated with clinical outcome. However, in HFpEF with AF, the use of BB was associated with reduced rehospitalization during the 6-month and 1-year follow up.

Keywords: Heart Failure; Atrial Fibrillation; β-blocker
INTRODUCTION

β-blockers (BBs) constitute a cornerstone of therapy in patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) based on the results of landmark trials. According to both European and American guidelines, the use of BBs in symptomatic patients with HFrEF has a class 1A recommendation. Nonetheless, there is a suboptimal utilization of recommended medications in patients at the greatest risk of death who are least likely to receive evidence-based therapy. BBs have not been fully evaluated in clinical trials, and there have been concerns regarding treatment efficacy, particularly in patients with acute decompensated HF, atrial fibrillation (AF), and HF with preserved ejection fraction.

Acute heart failure (AHF) is a life-threatening medical condition with high inpatient mortality (typically > 4%). However, evidence supporting the benefits of BB treatment (reduced mortality) in AHF is lacking and there are concerns about the negative inotropic effects of BBs; thus, the potential worsening of hemodynamics leads many physicians to stop BB treatment in AHF. The same concern about the beneficial effect of BB has been conclusively demonstrated to be inappropriate with regard to chronic HF management. On the other hand, AF is common in patients with HF because the pathophysiology and risk factors for HF and AF are closely associated. Furthermore, patients with concomitant HF and AF have significantly poorer prognoses. Although BBs are widely used in AF with and without HF as first-line control therapy, a recently performed meta-analysis of key BB randomized control trials (RCTs) involving chronic stable HFrEF patients showed that BBs were not effective in reducing all-cause mortality in patients with AF, but were effective in patients with normal sinus rhythm (NSR). In addition, no treatment to date has convincingly reduced morbidity or mortality in patients with HF with preserved ejection fraction (HFpEF) especially when combined with AF. Previous analyses in these patient subsets have lacked statistical power. Thus, the present study assessed whether BBs prescribed at discharge could improve prognosis in AHF patients with AF in a large nationwide prospective cohort.

METHODS

Study population
The Korean Acute Heart Failure (KorAHF) study is a multicenter prospective cohort study that enrolled 5,625 consecutive patients who were hospitalized for AHF at 10 tertiary university hospitals between March 2011 and February 2014. Detailed information on the study design and the results of the KorAHF registry has been provided previously. Briefly, the registry included patients with signs or symptoms of HF who met at least one of the following criteria: 1) lung congestion or 2) objective findings of left ventricular (LV) dysfunction or structural heart disease. From this population, we selected patients with HF and AF who had survived hospitalization with available 1-year follow-up data.

Study variables and clinical outcomes
HFrEF was defined as left ventricular ejection fraction (LVEF) < 40% and HFpEF as LVEF ≥ 50%. AF was confirmed with 12-lead electrocardiography at admission or during hospitalization. Patients who received only guideline-recommended BBs, including bisoprolol, carvedilol, sustained-release metoprolol succinate, and nebivolol at discharge, were considered as BB-treated. Patients not eligible for BB therapy whose systolic blood pressure was < 90 mmHg or resting heart rate was < 50 bpm at discharge were
In this study, the outcomes were defined as 60-day and 1-year all-cause mortality, rehospitalization because of aggravated HF, and a composite endpoint of mortality and HF rehospitalization. The attending physician collected follow-up data through a web-based case report form. The outcome data for subjects who were not followed up were ascertained by a telephone interview and confirmed from the National Death Records. All clinical events were monitored and verified by a Clinical Event Committee, comprising independent experts on HF who did not participate in patient enrollment for the study.14

Statistical analysis
Statistical analyses were conducted by the Center of Biomedical Data Science, Yonsei University, Wonju College of Medicine. Propensity score (PS) analysis was used to account for selection bias of BB prescription when assessing the association. The variables selected for the score were age, sex, body mass index, systolic blood pressure, heart rate at admission, history of hypertension, ischemic heart disease, chronic lung disease, chronic kidney disease, LVEF and other discharge medications including angiotensin converting enzyme inhibitor (ACEi), angiotensin-receptor II blocker (ARB), mineralocorticoid receptor antagonists (MRA), and anticoagulants. BB-treated and -untreated patients were then matched 1:1 using the nearest neighbor method with caliper < 0.01 and no replacement. Continuous variables were reported as mean ± standard deviation and were compared with the independent t-test. Categorical variables were presented as frequencies and percentages and were compared using the χ² test. Individual and composite clinical outcomes were analyzed based on time to the first event. Kaplan-Meier survival curves were plotted, and the groups were compared using the log-rank test. To assess the relationship between outcomes and use of BBs, Cox proportional hazards regression models were used and adjusted for sex, age, history of hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, and systolic blood pressure. The models also adjusted for heart rate, serum sodium levels, hemoglobin levels, creatinine levels, LVEF, discharge medication including ACEi or ARB, MRA and anticoagulation in the matching cohort. The proportional hazards assumption was confirmed using log (-log) survival plots and time interaction terms. In all cases, a P value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS Version 23.0 (IBM, Armonk, NY, USA).

Ethics statement
The study protocol was approved by the Institutional Review Board at each hospital and the Wonju Christian Hospital, Wonju College of Medicine, Yonsei University (Approval No. CR311003), and written informed consent was obtained from each patient or their relative or legal representative.

RESULTS
The number of AF patients eligible for BB therapy was 1,946 out of the 5,625 patients in the KorAHF registry. In addition, among these HF patients with AF, 936 were diagnosed HFrEF and 639 were HFpEF. BB was used in 543 (58%) patients with HFrEF and in 249 (40.0%) with HFpEF. After PS matching, the analysis was restricted to 1,140 patients: 670 HFrEF and 470 HFpEF.

Baseline characteristics and medication at discharge of HFrEF and AF
In HFrEF patients with AF, the median age of the cohort was 71 (interquartile range [IQR], 61–78) years and 62.1% were males. BB-treated and BB-untreated patients differed with regard
to most of the baseline characteristics (Table 1). Patients who did not receive BBs were older, had a lower body mass index and diastolic blood pressure, different pattern of comorbidities (more likely chronic kidney disease and obstructive pulmonary disease), different etiology of HF, and laboratory characteristics (lower levels of sodium and hemoglobin and lower ejection fraction). At discharge, other pharmacological therapies including ACEi and MRA were less frequently prescribed in BB-untreated patients (Supplementary Table 1). After PS matching, there were no statistically significant differences in baseline characteristics between BB-treated and BB-untreated patients, except in left bundle branch on the electrocardiogram and serum sodium levels (Table 1).

Baseline characteristics and medication at discharge of patients with HFrEF and AF
In HFrEF patients with AF, the median age of the cohort was 76 (IQR, 69–82) years and 36.8% were males. BB-untreated patients differed from the treated patients with regard to most of the baseline characteristics, as described in HFrEF (Table 2). BB-untreated patients had lower diastolic blood pressure, more likely hypertension, different etiologies of HF, and laboratory characteristics (lower levels of sodium, hemoglobin, left atrial dimension, and higher prevalence of left bundle branch block). At discharge, the prescription rate of other medication was not different between the groups (Supplementary Table 2). After PS matching, there were no statistically significant differences in baseline characteristics between BB-treated and BB-untreated patients, except in the etiology of HF and prevalence of left bundle branch block (Table 2).

Association between BB use and outcomes for patients with HFrEF and AF
At discharge in the matched cohort, the heart rate was significantly lower in BB-treated patients (75.3 ± 14.4 bpm vs. 78.5 ± 13.7 bpm, P < 0.01) and systolic blood pressure at 1-year follow up was lower in BB-treated patients (113.5 ± 16.4 mmHg vs. 117.6 ± 16.6 mmHg, P < 0.01) (Supplementary Table 3). In the overall cohort of HFrEF patients, 187 (20%) patients died from any cause and 184 (19.7%) were hospitalized due to worsening HF. All clinical events occurred more frequently in BB-untreated patients except 60-day rehospitalization (Supplementary Table 4); however, after PS matching, there was no difference in clinical outcomes (Supplementary Table 4). Event-free survival was not different according to the use of BB (Fig. 1), and after adjusting for covariates in the multivariable Cox model of matching cohort, there was no association between BB treatment and all clinical outcomes at the 60-day and 1-year follow up (Fig. 2). This statistical significance did not change after including digoxin and amiodarone at discharge as covariates (Supplementary Table 5).

In an exploratory subgroup analysis for 1-year rehospitalization and mortality, no significant interactions were observed at clinical cutoffs for variables, including age, sex, history of hypertension, diabetes mellitus, ischemic heart disease, myocardial infarction, chronic obstructive lung disease, type of HF, heart rate at admission and at discharge, as well as concomitant use of digoxin and amiodarone. However, in the subgroup of patients who had a history of myocardial infarction, the rate of rehospitalization (HR, 0.34; 95% CI, 0.13–0.88) and mortality (HR, 0.17; 95% CI, 0.06–0.49) was significantly lower in BB treated patients (Supplementary Fig. 1).

Association between BB use and outcomes for patients with HFrEF and AF
Heart rate was significantly lower in BB-treated patients at discharge and 1-year follow up (74.9 ± 13.1 bpm vs. 79.0 ± 13.9 bpm, P = 0.001) (76.7 ± 15.9 bpm vs. 82.5 ± 19.4 bpm, P = 0.01)
Table 1. Baseline characteristics of patients with heart failure with reduced ejection fraction and atrial fibrillation according to the use of β-blockers

| Characteristics                              | Overall cohort | Matched cohort | P value | Standardized difference, % |
|----------------------------------------------|---------------|----------------|---------|-----------------------------|
| **Demographic characteristic**              |               |                |         |                             |
| Male                                         | 342 (63.0)    | 239 (60.8)     | 0.500   |                              |
| Age, yr                                      | 67.5 ± 13.2   | 70.5 ± 12.6    | 0.001   | 69.8 ± 12.1                 |
| Height, cm                                   | 163.2 ± 9.3   | 161.7 ± 9.7    | 0.018   | 162.5 ± 9.3                 |
| Weight, cm                                   | 63.4 ± 13.6   | 59.8 ± 12.5    | < 0.001 | 61.2 ± 11.8                 |
| BMI, kg/m²                                   | 23.6 ± 3.8    | 22.8 ± 3.7     | < 0.001 | 23.1 ± 3.5                  |
| sBP, mmHg                                    | 1277 ± 271    | 1260.0 ± 27.4  | 0.339   | 126.3 ± 26.4                |
| dBP, mmHg                                    | 810 ± 19.3    | 778 ± 16.7     | 0.008   | 79.5 ± 18.8                 |
| Heart rate, beat/min                         | 99.0 ± 28.7   | 101.3 ± 29.5   | 0.225   | 100.8 ± 30.1                |
| NYHA functional class                        | 0.226         |                |         | 0.162                       |
| Class II                                     | 70 (12.9)     | 51 (13.0)      |         | 42 (12.5)                   |
| Class III                                    | 228 (42.0)    | 144 (36.6)     |         | 141 (42.1)                  |
| Class IV                                     | 245 (46.1)    | 198 (50.4)     |         | 152 (45.4)                  |
| De novo heart failure                        | 280 (51.6)    | 156 (39.7)     | < 0.001 | 163 (48.7)                  |
| **Comorbidity**                              |               |                |         |                             |
| Hypertension                                 | 309 (56.9)    | 207 (52.7)     | 0.199   | 184 (54.9)                  |
| DM                                           | 176 (32.4)    | 107 (27.2)     | 0.088   | 106 (28.2)                  |
| IHD                                          | 127 (23.5)    | 95 (24.2)      | 0.817   | 79 (21.7)                   |
| MI                                           | 84 (15.6)     | 57 (13.0)      | 0.269   | 53 (15.9)                   |
| CKD                                          | 54 (9.9)      | 65 (16.5)      | 0.003   | 44 (13.1)                   |
| COPD                                         | 55 (10.1)     | 58 (14.8)      | 0.032   | 45 (13.4)                   |
| MRA                                          | 110 (20.3)    | 91 (23.2)      | 0.287   | 72 (21.5)                   |
| **Medication at admission**                  |               |                | 0.038   | 0.380                       |
| ACEi                                         | 89 (12.7)     | 62 (15.8)      | 0.182   | 36 (10.7)                   |
| ARB                                          | 137 (25.2)    | 111 (28.2)     | 0.302   | 81 (24.2)                   |
| BBs                                          | 197 (36.3)    | 72 (18.3)      | < 0.001 | 126 (37.6)                  |
| MRA                                          | 110 (20.3)    | 91 (23.2)      | 0.287   | 72 (21.5)                   |
| **Etiology of heart failure**                |               |                | 0.038   | 0.380                       |
| IHD                                          | 146 (26.9)    | 123 (31.3)     | 0.182   | 95 (28.4)                   |
| VHD                                          | 50 (9.2)      | 65 (16.5)      | 0.047   | 37 (11.0)                   |
| Cardiomyopathy                               | 166 (30.6)    | 97 (24.7)      | 0.003   | 101 (30.1)                  |
| HHD                                          | 12 (2.2)      | 5 (1.3)        | 0.155   | 5 (1.5)                     |
| Tachycardia induced                          | 127 (23.4)    | 78 (19.8)      | 0.003   | 77 (23.0)                   |
| ECG characteristics at admission             |               |                | 0.038   | 0.380                       |
| LBBB                                         | 38 (7.0)      | 16 (4.1)       | 0.058   | 29 (8.7)                    |
| RBBB                                         | 31 (5.7)      | 29 (7.4)       | 0.303   | 18 (5.4)                    |
| **Laboratory characteristics at admission**  |               |                | 0.038   | 0.380                       |
| Na, mmol/L                                   | 138.1 ± 4.1   | 136.9 ± 5.2    | < 0.001 | 137.7 ± 4.2                 |
| K, mmol/L                                    | 4.4 ± 0.7     | 4.4 ± 0.6      | 0.047   | 4.4 ± 0.7                   |
| Albumin, g/dL                                | 3.7 ± 0.4     | 3.7 ± 0.5      | 0.576   | 3.7 ± 0.5                   |
| Hemoglobin, g/dL                             | 13.2 ± 2.3    | 12.8 ± 2.2     | 0.011   | 13.0 ± 2.3                  |
| Creatinine, mg/dL                            | 1.4 ± 1.2     | 1.5 ± 1.4      | 0.280   | 1.5 ± 1.3                   |
| hs-CRP, mg/dL                                | 1.9 ± 2.9     | 2.2 ± 4.0      | 0.390   | 1.9 ± 3.0                   |
| NT-proBNP, pg/mL                             | 9,562.4 ± 9,961.5 | 13577.11,488.5 | 0.091   | 10,573.6 ± 12,000.7        |
| BNP, pg/mL                                   | 1,360.1 ± 1,376.1 | 1,493.0 ± 1,442.8 | 0.393   | 1,412.9 ± 1,470.7          |
| CK-MB, ng/mL                                 | 5.5 ± 12.9    | 7.4 ± 22.3     | 0.014   | 5.3 ± 10.4                  |
| Troponin I, mg/mL                            | 0.8 ± 3.6     | 1.6 ± 8.3      | 0.092   | 0.8 ± 3.9                   |
| **Echocardiographic characteristics**        |               |                | 0.038   | 0.380                       |
| LVEF, %                                      | 27.7 ± 8.1    | 26.6 ± 8.2     | 0.041   | 271 ± 7.9                   |
| LVEDV, mL                                    | 1591 ± 67.8   | 1661 ± 72.4    | 0.192   | 158.6 ± 70.2                |
| LVESV, mL                                    | 115.5 ± 55.4  | 119.5 ± 57.9   | 0.354   | 116.0 ± 57.9                |
| LA dimension, mm                             | 50.7 ± 8.0    | 51.9 ± 10.8    | 0.063   | 50.6 ± 7.7                  |

Values are presented as numbers (%) or mean ± standard deviation. unless otherwise indicated.

BBs = β-blockers, BMI = body mass index, sBP = systolic blood pressure, dBP = diastolic blood pressure, NYHA = New York Heart Association, DM = diabetes mellitus, IHD = ischemic heart disease, MI = myocardial infarction, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists, VHD = valvular heart disease, HHD = hypertensive heart disease, ECG = electrocardiography, LBBB = left bundle branch block, RBBB = right bundle branch block, hs-CRP = high-sensitivity C-reactive protein, NT-proBNP = N-terminal pro-brain natriuretic peptide, BNP = B-type natriuretic peptide, CK-MB = Creatine kinase-MB, LVEF = left ventricular ejection fraction, LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, LA = left atrium.

https://jkms.org  https://doi.org/10.3346/jkms.2020.35.e278
| Characteristics                        | Overall cohort | Matched cohort | P value | Standardized difference, % |
|---------------------------------------|----------------|----------------|---------|----------------------------|
|                                       | BB treated     | BB untreated   |         |                            |
|                                       | (n = 249)      | (n = 390)      |         |                            |
|                                       | BB treated     | BB untreated   |         |                            |
|                                       | (n = 235)      | (n = 235)      |         |                            |
| Demographic characteristic at admission |                |                |         |                            |
| Male                                  | 93 (77.3)      | 142 (36.4)     | 0.810   |                            |
| Age, yr                               | 73.8 ± 11.3    | 73.7 ± 12.1    | 0.934   |                            |
| Height, cm                            | 157.6 ± 8.6    | 157.4 ± 9.5    | 0.859   |                            |
| Weight, cm                            | 591 ± 12.2     | 585 ± 12.4     | 0.540   |                            |
| BMI, kg/m²                            | 23.7 ± 4.0     | 23.5 ± 4.2     | 0.587   |                            |
| sBP, mmHg                             | 134.9 ± 28.2   | 133.3 ± 27.7   | 0.474   |                            |
| dBP, mmHg                             | 81.36 ± 18.6   | 77.8 ± 19.0    | 0.014   |                            |
| Heart rate, beat/min                  | 94.2 ± 26.9    | 90.8 ± 28.6    | 0.136   |                            |
| NYHA functional class                 | 0.746          | 0.920          |         |                            |
| Class II                              | 44 (17.7)      | 74 (19.0)      | 0.42    |                            |
| Class III                             | 94 (37.8)      | 154 (39.5)     |         |                            |
| Class IV                              | 111 (44.6)     | 162 (41.5)     |         |                            |
| De novo heart failure                 | 135 (52.4)     | 172 (44.1)     | 0.013   |                            |
| Comorbidty                            |                |                |         |                            |
| Hypertension                          | 189 (75.9)     | 240 (61.5)     | 0.001   |                            |
| DM                                    | 81 (35.2)      | 103 (26.4)     | 0.096   |                            |
| HHD                                   | 42 (16.9)      | 71 (18.2)      | 0.666   |                            |
| MI                                    | 18 (7.2)       | 24 (6.2)       | 0.593   |                            |
| CKD                                   | 24 (9.6)       | 32 (8.2)       | 0.532   |                            |
| COPD                                  | 28 (11.2)      | 60 (15.4)      | 0.139   |                            |
| Medication at admission               |                |                |         |                            |
| ACEi                                  | 15 (6.0)       | 26 (6.7)       | 0.746   |                            |
| ARB                                   | 78 (31.3)      | 132 (33.8)     | 0.508   |                            |
| BB                                    | 134 (53.8)     | 86 (22.1)      | 0.001   |                            |
| MRA                                   | 41 (16.5)      | 98 (25.1)      | 0.010   |                            |
| Etiology of heart failure             |                |                | 0.001   | 13.34                      |
| IHD                                   | 47 (18.9)      | 43 (11.0)      | 0.746   |                            |
| VHD                                   | 62 (24.9)      | 77 (19.8)      | 67 (28.5)| 106 (45.1)                |
| Cardiomyopathy                        | 20 (8.0)       | 21 (5.4)       | 18 (7.7)| 14 (6.0)                  |
| HHD                                   | 7 (2.8)        | 12 (3.1)       | 6 (2.6) | 8 (3.4)                   |
| Tachycardia induced                   | 85 (34.1)      | 87 (22.3)      | 77 (32.8)| 53 (22.6)                |
| ECG characteristics at admission      |                |                |         |                            |
| LBBB                                  | 0 (0.0)        | 6 (1.5)        | 0.049   |                            |
| RBBB                                  | 15 (6.0)       | 33 (8.5)       | 0.254   |                            |
| Laboratory characteristics at admission |            |                | 0.045   | 18.57                      |
| Na, mmol/L                            | 138.0 ± 4.6    | 126.7 ± 5.8    | 0.005   |                            |
| K⁺, mmol/L                            | 4.3 ± 0.6      | 4.3 ± 0.7      | 0.835   |                            |
| Albumin, g/dL                         | 3.8 ± 0.5      | 3.7 ± 0.5      | 0.50    |                            |
| Hemoglobin, g/dL                      | 12.4 ± 1.9     | 12.0 ± 2.1     | 0.018   |                            |
| Creatinine, mg/dL                     | 11 ± 0.7       | 12 ± 0.7       | 0.290   |                            |
| hs-CRP, mg/dL                         | 1.8 ± 3.2      | 2.0 ± 4.1      | 0.640   |                            |
| NT-proBNP, pg/mL                      | 5.976 ± 7.2190 | 5.595 ± 7.0710 | 0.637 | 6.034 ± 7.2007  |
| BNP, pg/mL                            | 815.7 ± 682.6  | 760.0 ± 926.2  | 0.575   | 820.5 ± 694.7  |
| CK-MB, ng/mL                          | 5.0 ± 14.9     | 6.6 ± 33.7     | 0.505   | 5.2 ± 15.3  |
| Tropinin I, mg/mL                     | 1.0 ± 4.3      | 1.3 ± 10.9     | 0.709   | 1.1 ± 4.5   |
| Echocardiographic characteristics    |                |                |         |                            |
| LVEF, %                               | 58.6 ± 6.5     | 58.4 ± 6.0     | 0.674   |                            |
| LVEDV, mL                             | 991 ± 46.4     | 1061 ± 44.2    | 0.395   | 100.3 ± 47.1 |
| LVESV, mL                             | 317 ± 5.8      | 32.3 ± 5.9     | 0.696   | 42.5 ± 25.5 |
| LA dimension, mm                      | 52.3 ± 9.0     | 54.6 ± 12.2    | 0.013   | 52.6 ± 9.0  |

Values are presented as numbers (%) or mean ± standard deviation, unless otherwise indicated.

BB = β-blockers, BMI = indicates body mass index, sBP = systolic blood pressure, dBP = diastolic blood pressure, NYHA = New York Heart Association, DM = diabetes mellitus, IHD = ischemic heart disease, MI = myocardial infarction, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists, VHD = valvular heart disease, HHD = hypertensive heart disease, ECG = electrocardiography, LBBB = left bundle branch block, RBBB = right bundle branch block, hs-CRP = high-sensitivity C-reactive protein, NT-proBNP = N-terminal pro-brain natriuretic peptide, BNP = B-type natriuretic peptide, CK-MB = Creatine kinase-MB, LVEF = left ventricular ejection fraction, LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, LA = left atrium.
Fig. 1. Sixty-day and 1-year event-free survival according to treatment with \(\beta\)-blockers in heart failure with reduced ejection fraction. (A) Heart failure hospitalization, (B) mortality, (C) composite endpoint at 60-day and (D-F) at 1 year (\(\beta\)-blocker treated, dotted line: \(\beta\)-blocker untreated).

|                | HR (95% CI)   | P-value |
|----------------|---------------|---------|
| HFrEF with AF  |               |         |
| 60-day heart failure rehospitalization | 0.75 (0.47-1.20) | 0.23 |
| 60-day mortality | 0.65 (0.37-1.13) | 0.13 |
| 60-day composite endpoint | 0.77 (0.53-1.11) | 0.16 |
| 1-year heart failure rehospitalization | 0.76 (0.54-1.07) | 0.12 |
| 1-year mortality | 0.81 (0.58-1.13) | 0.21 |
| 1-year composite endpoint | 0.80 (0.62-1.04) | 0.10 |
| HFpEF with AF   |               |         |
| 60-day heart failure rehospitalization | 0.38 (0.20-0.74) | <0.01 |
| 60-day mortality | 0.61 (0.25-1.50) | 0.28 |
| 60-day composite endpoint | 0.44 (0.26-0.75) | <0.01 |
| 1-year heart failure rehospitalization | 0.53 (0.34-0.82) | <0.01 |
| 1-year mortality | 0.82 (0.54-1.27) | 0.38 |
| 1-year composite endpoint | 0.61 (0.44-0.85) | <0.01 |

Fig. 2. Forest plot of clinical outcomes of the \(\beta\)-blocker-treated group compared to those of the untreated group. HR = hazard ratio, CI = confidence interval, HFrEF = heart failure with reduced ejection fraction, AF = atrial fibrillation.
In the overall cohort of HFpEF patients, 123 (19.2%) patients died and 123 (19.2%) were rehospitalized. BB-untreated patients were more frequently hospitalized at the 60-day (12.3% vs. 5.2%, \( P < 0.01 \)) and 1-year follow up (13.3% vs. 23.1%, \( P < 0.01 \)), but mortality was not different (Supplementary Table 6). In addition, the 60-day and 1-year rehospitalization free survival rates were more favorable in BB-treated patients (Fig. 3). After PS matching, the higher occurrence of 6-month and 1-year rehospitalization in BB-untreated patients was also confirmed (Supplementary Table 6), while rehospitalization-free survival during the 6-month and 1-year follow-up was higher in BB users (Fig. 2). Furthermore, in the multivariable Cox model of the PS-matched cohort, BB use was associated with reduced 6-month (HR, 0.38; 95% CI, 0.20–0.74) and 1-year rehospitalization (HR, 0.53; 95% CI, 0.34–0.82). Because of reduced rehospitalization, BB use was associated with reduction of 6-month and 1-year composite endpoint (Fig. 2). This statistical significance also did not change after including digoxin and amiodarone at discharge as covariates (Supplementary Table 5). In a subgroup analysis for 1-year rehospitalization, there was significant interaction in patients with concomitant use of digoxin (\( P \) for interaction = 0.03). For 1-year mortality, significant interaction was observed for age (\( P \) for interaction = 0.03) (Supplementary Fig. 2).

Fig. 3. Sixty-day and 1-year event-free survival according to the treatment of \( \beta \)-blocker in heart failure with preserved ejection fraction. (A) heart failure hospitalization, (B) mortality, (C) composite endpoint at 60-day and (D-F) at 1 year (\( \beta \)-blocker treated, dotted line: \( \beta \)-blocker untreated).
Our analysis showed that there was no significant implication of BB on 60-day and 1-year clinical outcomes in HFrEF patients with AF. However, the use of BB in HfPpEF with AF was associated with reduced rehospitalization rates at 6-month and 1-year follow up.

**BBs and outcomes in HFrEF with AF**

Evidence-based benefits, including reduced ejection fraction (HFrEF) and NSR, of guideline-directed therapy for HF have been documented but there are limited and conflicting data regarding the prognostic implications of guideline-directed therapy for HFrEF patients with AF. In our previous study, a higher level of adherence to guidelines was associated with better 60-day and 1-year prognoses in HFrEF patients with AF. The current guideline recommends BBs as a cornerstone therapy of HFrEF and it is based on clinical trials that demonstrated an improvement in clinical outcomes in HF patients. However, RCTs examining the efficacy of BBs in HF patients with concomitant AF, especially patients admitted to hospital with AHF, are scarce. Meta-analysis studies and cohort data have reported the efficacy of BBs in HFrEF patients with AF but results are conflicting. A recent meta-analysis evaluating the use of BBs in HFrEF patients with AF documented that BBs did not reduce mortality in HF patients with AF,\textsuperscript{11,12,16} Additionally, in a meta-analysis of four RCTs evaluating HFrEF with AF, BB showed reduced mortality in NSR (HR, 0.63; 95% CI, 0.54–0.73; \( P < 0.001 \)), but did not reduce mortality in AF patients (HR, 0.86; 95% CI, 0.66–1.13; \( P = 0.28 \)).\textsuperscript{11} In another meta-analysis using individual-patient data, BB therapy did not lead to a significant reduction in all-cause mortality in patients with AF (HR, 0.97; 95% CI, 0.83–1.14; \( P = 0.73 \)).\textsuperscript{12} In contrast to these meta-analyses, cohort studies have reported positive results for BBs. In the report from the Swedish Heart Failure Registry, BBs showed a protective effect on mortality (HR, 0.71; 95% CI, 0.61–0.84; \( P < 0.001 \)).\textsuperscript{17} In the Danish nationwide cohort, evidence of a lower mortality with BB therapy was observed in the PS-matched analysis (HR, 0.75; 95% CI, 0.71–0.79).\textsuperscript{18}

Although the exact reason is not clear in this study, there are several possible explanations for the conflicting results of the effects of BB therapy in HFrEF patients with AF. First, there are several mechanisms for the beneficial effects of BBs. One of the most important is the reduction of the heart rate and not a blockage of central sympathetic outflow.\textsuperscript{19} In HFrEF with NSR, lower heart rate has a better outcome with or without BBs.\textsuperscript{16,20} However, heart rate has no prognostic implications in patients with AF.\textsuperscript{16,20} Patients with AF may need a higher heart rate to maintain a similar cardiac output; higher heart rate might be needed during HF. Further, a low heart rate in AF may be an expression of an underlying conduction disorder, which itself may be associated with impaired outcome.\textsuperscript{11} Second, AF in patients with HF may be a marker of a poorer clinical condition, leading to a worse outcome that is less modifiable by BB therapy.\textsuperscript{21}

**BB and outcomes in HfPpEF with AF**

Evidence that BBs improve symptoms is conflicting in HfPpEF patients even with NSR.\textsuperscript{13} In a recent individual patient meta-analysis, BBs were effective in HFrEF but not in HfPpEF patients with NSR or AF.\textsuperscript{22} Though the exact mechanism for the lack of positive prognostic effect of BBs in patients with HfPpEF is not known, there is a possible explanation. In the pathophysiological view, the beneficial effect of BBs is mediated by a reduction of the resting heart rate in NSR. The hemodynamic effects of acute change of heart rate in patients with HfPpEF have been reported to be different compared with those in patients with normal ventricular function.\textsuperscript{23} Increasing heart rate decreased LV end-diastolic pressure strikingly, while end-diastolic, end-systolic, and stroke volumes all declined. These hemodynamic
Effects were similar in the groups with and without BBs. Further, because LV end-diastolic pressure declines substantially with heart rate elevations in HFP EF, it is likely that slowing the resting heart rate will raise filling pressures. Because increases in the heart rate in patients with HFP EF were associated with LV volume reductions that resulted in a blunted heart rate—cardiac output relationship, slowing of the resting heart rate may modestly reduce the cardiac output. This, along with increased filling pressures, is obviously undesirable in patients with HFP EF and suggests that higher resting heart rate provides hemodynamic benefits. No study has been conducted on chronic resting heart rate elevation in HFP EF. In the RACE II trial (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison Between Lenient Versus Strict Rate Control II) including a high proportion of cases with hypertensive heart disease and diastolic dysfunction, a more lenient heart rate control strategy of up to 110 per minutes was non-inferior to strict control strategy. This could provide the clue that different significance of HR in HFP EF especially combined with AF.

However, there were some studies reporting contradictory results for the association between heart rate and prognosis in HFP EF. The data from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry reported that heart rate <70 beats/min was also associated with a lower risk for the combined endpoint of HF readmission or all-cause mortality (HR, 0.90; 95% CI, 0.84–0.96; P = 0.002). Recently the data based on the Swedish Heart Failure Registry demonstrated that higher heart rate was associated with increased mortality during the initial years of follow-up in HFP EF with AF. In a large-scale cohort study, BB was associated with reduced mortality (HR, 0.93; 95% CI, 0.86–0.996; P = 0.04). Although the exact reason is not clear in this study, BB was associated with reduced 6-month and 1-year rehospitalization. There can be several hypotheses. First, HFP EF might be over diagnosed in patients with HFP EF and AF because symptoms might reflect AF alone. BBs could have reduced symptoms associated with AF and this could give rise to reduction in rehospitalization. Second, heart rate reduction with BBs in HFP EF with AF could have prevented tachycardia-induced HF and rehospitalization. In this study, heart rate was lower in the BB-treated group during follow up (Supplementary Table 3).

Several limitations of the present study should be noted and caution is needed in the interpretation. First, because the sample size was relatively small, this study might be underpowered. There is the possibility of a type II error, especially in HF rehospitalization, because the survival curves of patients with HFrEF, especially rehospitalization, diverge. We calculated the power for rehospitalization outcome in HFrEF patients. A two-sided test of whether the HR was one with an overall sample size of 748 subjects (of which 335 are in the control group and 335 are in the treatment group) achieved 32% power at a 0.050 significance level when the HR was actually 0.699. It was anticipated that proportions of subjects having the event during the study should be 0.123 for the control group and 0.087 for the treatment group. This study was not powered to investigate several outcomes, especially the influence of BB on rehospitalization. Thus, the present findings might be due to a Type II error. Second, subgroup analysis had many limitations because of the small sample size. In the report from the Swedish Heart Failure Registry, heart rate >100 beats per minute was associated with an increased mortality in HFrEF with AF. In this study, the number of patients with heart rate > 100 beats per minute on discharge was small; hence, subgroup analysis for the patients with a high heart rate could not be performed. In addition, BB has more pronounced prognostic implication in patients with a history of myocardial infarction. However, the number of patients with a history of myocardial infarction was very small in patients with HFP EF and AF; therefore, subgroup analysis was not possible in these patients. In the myocardial infarction
and ischemic heart disease subgroup, the insignificant interaction for 1-year mortality might also be caused by the small sample size. Third, this observational cohort study was likely subject to selection bias, because treatment was entirely dependent on the attending physician’s decision. The PS matching method was applied to balance confounders as much as possible; however, because of the limited sample size, few variables were available for extensive adjustment using PS matching. The Cox regression models were then constructed to adjust for baseline confounders to reduce residual confounders as much as possible, although we could not rule out potential unmeasured confounders. Fourth, AF-specific information was limited, as AF diagnosis was based on electrocardiography at admission or during hospitalization; this may have led to an underestimation of AF. Finally, the purpose of this study was to evaluate whether BB therapy at discharge has prognostic implications. Treatment with BB was defined at discharge and the likely crossover throughout the follow-up; hence, this might have interfered with the potential associations with outcomes (Supplementary Fig. 3). Moreover, BB-untreated patients may have been at a higher risk due to past intolerance or perceived risk of future intolerance. With decreasing numbers of patients at risk and increasing crossover patients over time, findings at longer durations of follow-up should be interpreted with caution and may underestimate benefits associated with BB use.

In conclusion, the use of BBs at discharge was not associated with clinical outcomes at the 60-day and 1-year follow-ups in real-world hospitalized patients with HFrEF and AF. In HFrEF with AF, BB was only associated with lower incidence of rehospitalization at the 6-month and 1-year follow up. Further investigations are required for the development of optimal therapeutic options for this patient subgroup.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Medical therapy at discharge in patients with heart failure with reduced ejection fraction with atrial fibrillation

Click here to view

Supplementary Table 2
Medical therapy at discharge in patients with heart failure with preserved ejection fraction and atrial fibrillation

Click here to view

Supplementary Table 3
Changes of pulse rate and blood pressure in matched cohort during follow up

Click here to view

Supplementary Table 4
Clinical outcomes in patients with heart failure with reduced ejection fraction with atrial fibrillation

Click here to view
Supplementary Table 5
Multivariate adjusted risk-adjusted beta blocker-outcome link including digoxin and amiodarone at discharge

Click here to view

Supplementary Table 6
Clinical outcomes in patients with heart failure with preserved ejection fraction with atrial fibrillation

Click here to view

Supplementary Fig. 1
The subgroup in heart failure with reduced ejection fraction. (A) for 1-year rehospitalization and (B) for 1-year mortality.

Click here to view

Supplementary Fig. 2
The subgroup in heart failure with preserved ejection fraction. (A) for 1-year rehospitalization and (B) for mortality.

Click here to view

Supplementary Fig. 3
Change rate of beta-blocker therapy during follow up.

Click here to view

REFERENCES

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128(16):1810-52.
PUBMED | CROSSREF

2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-200.
PUBMED | CROSSREF

3. Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA 2005;294(10):1240-7.
PUBMED | CROSSREF

4. Harjola VP, Follath F, Nieminen MS, Brutsaert D, Dickstein K, Drexler H, et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12(3):239-48.
PUBMED | CROSSREF

5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001-7.
PUBMED | CROSSREF

6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353(9146):9-13.
PUBMED | CROSSREF
7. Packer M, Coats AJ, Fowler MB, Katus HA, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344(22):1651-8.

8. Chiang CE, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O’Neill J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. *Circ Arrhythm Electrophysiol* 2012;5(4):632-9.

9. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation* 2003;107(23):2920-5.

10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2014;64(21):e1-76.

11. Rienstra M, Damman K, Mulder BA, Van Gelder IC, McMurray JJ, Van Veldhuisen DJ. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. *JACC Heart Fail* 2013;1(1):21-8.

12. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;384(9961):2235-43.

13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;18(8):891-975.

14. Lee SE, Cho HJ, Lee HY, Yang HM, Choi JO, Jeon ES, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. *Eur J Heart Fail* 2014;16(6):700-8.

15. Ahn MS, Yoo BS, Yoon J, Lee SH, Kim JY, Ahn SG, et al. Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation. *Heart* 2020;106(4):292-8.

16. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. *J Am Coll Cardiol* 2017;69(24):2885-96.

17. Li SJ, Sartipy U, Lund LH, Dahlström U, Adiels M, Petzold M, et al. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish Heart Failure Registry. *Circ Heart Fail* 2015;8(5):871-9.

18. Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Lip GY. β-blockers in atrial fibrillation patients with or without heart failure: association with mortality in a nationwide cohort study. *Circ Heart Fail* 2016;9(2):e002597.

19. Colh IN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 2003;5(5):659-67.

20. Simpson J, Castagno D, Doughty RN, Poppe KK, Earle N, Squire I, et al. Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. *Eur J Heart Fail* 2015;17(11):1182-91.

21. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. *J Am Coll Cardiol* 2006;47(10):1997-2004.
22. Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018;39(1):26-35.

23. Wachter R, Schmidt-Schweda S, Westermann D, Post H, Edelmann F, Kasner M, et al. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. *Eur Heart J* 2009;30(24):3027-36.

24. Meyer M, LoWinter MM. Heart rate and heart failure with preserved ejection fraction: time to slow β-blocker use? *Circ Heart Fail* 2019;12(8):e006213.

25. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;362(15):1363-73.

26. Lam PH, Dooley DJ, Deedwania P, Singh SN, Bhatt DL, Morgan CJ, et al. Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2017;70(15):1861-71.

27. Sartipy U, Savarese G, Dahlström U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. *Eur J Heart Fail* 2019;21(4):471-9.

28. Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. *JAMA* 2014;312(19):2008-18.